Spinal Cord Injury Therapeutics Market Will Grow At Highest Pace Owing To Rising Geriatric Population
Spinal Cord Injury Therapeutics Market |
The spinal cord injury therapeutics market consists of therapeutic drugs for the treatment of spinal cord injury. Spinal cord injuries can cause pain, paralysis, and loss of sensation below the site of injury. There are currently no approved therapies that can regenerate injured spinal cord tissues and restore motor or sensory functions. However, neuroprotective, stem cell-based, and biomaterial-based therapies aim to promote tissue repair and prevent secondary injuries after spinal cord damage.
The global spinal cord injury therapeutics market is estimated to be valued at US$ 8.53 billion in 2024 and is expected to exhibit a CAGR of 14% over the forecast period of 2024 to 2031.
Key Takeaways
Key players operating in the spinal cord injury therapeutics are Xinyi Solar Holdings Limited , Flat Glass Group Co., Ltd. ,Nippon Sheet Glass Co., Ltd. Key players are increasingly investing in R&D to develop novel drug candidates and combination therapies. The growing geriatric population is susceptible to age-related spinal cord injuries, fueling market growth. Advancements in stem cell therapies, nanotechnology, and biomaterial scaffolds offer hope for repairing and regenerating damaged spinal cords.
Market trends
Rising investment in regenerative medicine research for spinal cord injuries is a key trend. Stem cell therapies that promote regeneration of neurons and myelin sheaths are being explored. Biomaterials that mimic the extracellular matrix and support regrowth of nerves are also in development.
Market Opportunities
The growing geriatric population prone to spinal cord injuries due to age-related degeneration presents lucrative opportunities. Combination therapies using biomaterials, stem cells, and neuroprotective drugs have high commercialization potential. Geographies with insufficient spine injury medical infrastructure like Asia Pacific offer scope for market players.
Impact of COVID-19 on Spinal Cord Injury Therapeutics Market
The COVID-19 pandemic has significantly impacted the Spinal Cord Injury Therapeutics Market Demand. Lockdowns and social distancing measures imposed worldwide led to disruptions in clinical trials, manufacturing operations and delayed new product launches. With hospitals diverting resources to treat COVID-19 patients, elective surgeries including spinal procedures were postponed. This negatively impacted the demand for spinal cord injury therapeutics in 2020. However, with rising vaccination rates globally and easing of restrictions in 2021, the market is recovering gradually.
Pre-pandemic, the market was growing at a healthy rate driven by increasing incidence of spinal cord injuries, growing geriatric population and approval of novel therapies. Advancements in cell therapy, gene therapy and neuroregeneration were expanding treatment options. Companies were actively conducting clinical trials and bringing new products to market. However, COVID-19 slowed down research progress and stalled pipeline development temporarily. Post-pandemic, the market is expected to witness renewed growth on the back of pent-up demand, resumption of elective surgeries and restarting of delayed clinical studies. Companies are likely to accelerate pipeline development and new product launches to make up for lost time. Telehealth and digital healthcare can play a bigger role in remote patient monitoring and management going forward.
Asia Pacific is currently the most lucrative geographic region for the spinal cord injury therapeutics market in terms of value. Countries like China, Japan and India have a huge patient population suffering from spinal cord injuries as a result of improving survival rates of trauma patients and high incidences of falls and accidents. Further, growing medical infrastructure, increasing healthcare spending and expanding healthcare coverage are aiding market growth in Asia Pacific. Emerging economies in the region offer immense scope for market players to tap new customers.
Europe accounts for the fastest revenue growth rate for the spinal cord injury therapeutics market globally. Significant presence of leading medical device companies, rising clinical research funding and adoption of advanced technologies have accelerated market expansion in Europe. Availability of reimbursements for spinal cord injury treatment as well as growing aging population at high risk of spinal injuries are fueling demand. Additionally, awareness programs and initiatives by spinal cord injury patient associations have bolstered market growth trajectories in European countries.
Get more insights on Spinal Cord Injury Therapeutics Market
Comments
Post a Comment